Description Module

Description Module

The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.

Description Module path is as follows:

Study -> Protocol Section -> Description Module

Description Module


Ignite Creation Date: 2025-12-24 @ 12:34 PM
Ignite Modification Date: 2025-12-24 @ 12:34 PM
NCT ID: NCT00053261
Brief Summary: RATIONALE: Vaginal changes that may effect sexual function occur in patients undergoing treatment for cervical cancer. PURPOSE: Clinical trial to determine the type of vaginal changes such as vaginal dryness that occur in patients receiving treatment for cervical cancer and the effect these changes have on sexual function.
Detailed Description: OBJECTIVES: * Obtain estimates of changes in vaginal length, perceived vaginal elasticity, perceived vaginal lubrication, and sexual activity, response, and satisfaction among patients with stage IB2 cervical cancer. * Compare these differences between the patients in the two treatment groups in GOG-0201. * Determine the relationships between vaginal dilation activities and vaginal length changes in these patients. * Determine the association between smoking and vaginal length and between smoking and vaginal dryness in these patients after therapy for cervical cancer. * Assess the extent of subject interest in and preferred methods of sexual counseling related to problems resulting from treatment in these patients. OUTLINE: Vaginal length is measured using Vaginal Sound, a modified plastic vaginal dilator. The data about vaginal elasticity and lubrication and sexual activity, response, and satisfaction are obtained from patient self-report, as well as vaginal dilation activities. Measurement and assessments are taken before treatment and then at 3, 6, 12, and 24 months. Patients are followed every 3 months for 2 years. PROJECTED ACCRUAL: Approximately 150 patients will be accrued for this study.
Study: NCT00053261
Study Brief:
Protocol Section: NCT00053261